9 reasons for choosing mometasone furoate Review article
Article Sidebar
Published:
Mar 31, 2015
Keywords:
allergic rhinitis, rhinosinusitis, therapy, intranasal corticosteroids, mometasone furoate
Main Article Content
Abstract
Intranasal corticosteroids are currently the most effective anti-inflammatory drugs in the treatment of allergic rhinitis, acute and chronic rhinosinusitis and chronic rhinosinusitis with or without nasal polyps. Nonquestionable advantage of intranasal corticosteroids is their strong anti-inflammatory local action and little impact on general health. According to PoSLeNN and ARIA 2010 recommendations intranasal corticosteroids are considered the first line drugs for moderate and severity intermittent and all stages of persistent allergic rhinitis. The paper presents distinguishing features of mometasone furoate.
Article Details
How to Cite
Rapiejko , P. (2015). 9 reasons for choosing mometasone furoate. Medycyna Faktow (J EBM), 8(1(26), 50-55. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2324
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Brożek J.L., Bousquet J., Baena-Cagnani C.E. et al.: Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revison. J. Allergy Clin. Immunol. 2010; 126: 466-476.
2. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12.
3. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013, S1.
4. Rapiejko P., Jurkiewicz D.: Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia 2014; 22(10): 27-35.
5. Mygind N.: Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ 1973; 4: 464-466.
6. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids’ introduction. Otolaryngol Pol. 2014; 68(2): 51-64.
7. Meltzer E.O., Shekar T., Teper A.A.: Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011; 32(2): 159-167.
8. Penagos M., Compalati E., Tarantini F. et al.: Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008; 63(10): 1280-1291.
9. Small C.B., Hernandez J., Reyes A. et al.: Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J. Allergy Clin. Immunol. 2005; 116(6): 1275-1281.
10. Wei C.C., Kennedy D.W.: Mometasone implant for chronic rhinosinusitis. Med Devices (Auckl) 2012; 5: 75-80.
11. Svensson J., Lundberg J., Olsson P. et al.: Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Prim. Care Respir. J. 2012; 21(4): 412-418.
12. Rapiejko O.P., Zawisza E., Lipiec A. et al.: Wspomaganie antybiotykoterapii zapalenia zatok przynosowych glikokortykosteroidem prosluzanem mometazonu, stosowanym donosowo. Terapia 2001; 3.
13. Baena-Cagnani C.E., Patel P.: Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr. Med. Res. Opin. 2010; 26: 2047-2055.
14. Baldwin C.M., Scott L.J.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 2008; 68: 1723-1739.
15. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroid: clinical and therapeutic implications. Allergy 2008; 63: 1292-1300.
16. Sörensen H., Mygind N., Pedersen C.B. et al.: Long-term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol. (Stockh) 1976; 82: 260-262.
17. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16-33.
18. Daley-Yates P.T., Kunka R.L., Yin Y. et al.: Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004; 60(4): 265-268.
19. Schenkel E.J., Skoner D.P., Bronsky E.A. et al.: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: e22.
20. Bruni F.M., De Luca G., Venturoli V. et al.: Intranasal corticosteroids and adrenal suppression. Neroimmunomodulation 2009; 16: 353-362.
21. Brannan M.D., Herron J.M., Affrime M.B.: Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Therapeutics. 1997; 19: 1330-1339.
22. Anolik R., Pearlman D., Teper A. et al.: Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc. 2009; 30: 406-412.
23. Ratner P.H., Meltzer E.O., Teper A.: Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int. J. Pediatr. Otorhinolaryngol. 2009; 73: 651-657.
24. Wandalsen G.F., Mendes A.I., Solé D.: Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am. J. Rhinol. Allergy 2010; 24: e32-e36.
25. Minshall E., Ghaffar O., Cameron L. et al.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998; 118: 648-654.
26. Sharpe S.A., Sandweiss V., Tuazon J. et al.: Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev. Ind. Pharm. 2003; 29: 1005-1012.
27. Salapatek A.M., Patel P., Gopalan G. et al.: Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am. J. Rhinol. Allergy 2010; 24: 433-438.
28. Charakterystyka Produktu Leczniczego. Nasometin.
29. Charakterystyka Produktu Leczniczego. Pronasal.
2. Fokkens W.J., Lund V.J., Mullol J. et al.: EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology 2012; 50(1): 1-12.
3. Samoliński B., Arcimowicz M. (red.): Polskie Standardy Leczenia Nieżytów Nosa (PoSLeNN). Alergologia Polska 2013, S1.
4. Rapiejko P., Jurkiewicz D.: Donosowe glikokortykosteroidy w leczeniu nieżytów nosa. Terapia 2014; 22(10): 27-35.
5. Mygind N.: Local effect of intranasal beclomethasonedipropionate aerosol in hay fever. BMJ 1973; 4: 464-466.
6. Samoliński B., Nowicka A., Wojas O. et al.: Intranasal glucocorticosteroids – not only in allergic rhinitis In the 40th anniversary of intranasal glucocorticosteroids’ introduction. Otolaryngol Pol. 2014; 68(2): 51-64.
7. Meltzer E.O., Shekar T., Teper A.A.: Mometasone furoate nasal spray for moderate-to-severe nasal congestion in subjects with seasonal allergic rhinitis. Allergy Asthma Proc. 2011; 32(2): 159-167.
8. Penagos M., Compalati E., Tarantini F. et al.: Efficacy of mometasone furoate nasal spray in the treatment of allergic rhinitis. Meta-analysis of randomized, double-blind, placebo-controlled, clinical trials. Allergy 2008; 63(10): 1280-1291.
9. Small C.B., Hernandez J., Reyes A. et al.: Efficacy and safety of mometasone furoate nasal spray in nasal polyposis. J. Allergy Clin. Immunol. 2005; 116(6): 1275-1281.
10. Wei C.C., Kennedy D.W.: Mometasone implant for chronic rhinosinusitis. Med Devices (Auckl) 2012; 5: 75-80.
11. Svensson J., Lundberg J., Olsson P. et al.: Cost-effectiveness of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Prim. Care Respir. J. 2012; 21(4): 412-418.
12. Rapiejko O.P., Zawisza E., Lipiec A. et al.: Wspomaganie antybiotykoterapii zapalenia zatok przynosowych glikokortykosteroidem prosluzanem mometazonu, stosowanym donosowo. Terapia 2001; 3.
13. Baena-Cagnani C.E., Patel P.: Efficacy and long-term safety of mometasone furoate nasal spray in children with perennial allergic rhinitis. Curr. Med. Res. Opin. 2010; 26: 2047-2055.
14. Baldwin C.M., Scott L.J.: Mometasone furoate. A review of its intranasal use in allergic rhinitis. Drugs 2008; 68: 1723-1739.
15. Derendorf H., Meltzer E.O.: Molecular and clinical pharmacology of intranasal corticosteroid: clinical and therapeutic implications. Allergy 2008; 63: 1292-1300.
16. Sörensen H., Mygind N., Pedersen C.B. et al.: Long-term treatment of nasal polyps with beclomethasone dipropionate aerosol. III. Morphological studies and conclusions. Acta Otolaryngol. (Stockh) 1976; 82: 260-262.
17. Passalacqua G., Albano M., Canonica G.W. et al.: Inhaled and nasal corticosteroids: safety aspects. Allergy 2000; 55: 16-33.
18. Daley-Yates P.T., Kunka R.L., Yin Y. et al.: Bioavailability of fluticasone propionate and mometasone furoate aqueous nasal sprays. Eur. J. Clin. Pharmacol. 2004; 60(4): 265-268.
19. Schenkel E.J., Skoner D.P., Bronsky E.A. et al.: Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics 2000; 105: e22.
20. Bruni F.M., De Luca G., Venturoli V. et al.: Intranasal corticosteroids and adrenal suppression. Neroimmunomodulation 2009; 16: 353-362.
21. Brannan M.D., Herron J.M., Affrime M.B.: Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin. Therapeutics. 1997; 19: 1330-1339.
22. Anolik R., Pearlman D., Teper A. et al.: Mometasone furoate improves nasal and ocular symptoms of seasonal allergic rhinitis in adolescents. Allergy Asthma Proc. 2009; 30: 406-412.
23. Ratner P.H., Meltzer E.O., Teper A.: Mometasone furoate nasal spray is safe and effective for 1-year treatment of children with perennial allergic rhinitis. Int. J. Pediatr. Otorhinolaryngol. 2009; 73: 651-657.
24. Wandalsen G.F., Mendes A.I., Solé D.: Objective improvement in nasal congestion and nasal hyperreactivity with use of nasal steroids in persistent allergic rhinitis. Am. J. Rhinol. Allergy 2010; 24: e32-e36.
25. Minshall E., Ghaffar O., Cameron L. et al.: Assessment by nasal biopsy of long-term use of mometasone furoate aqueous nasal spray (Nasonex) in the treatment of perennial rhinitis. Otolaryngol. Head Neck Surg. 1998; 118: 648-654.
26. Sharpe S.A., Sandweiss V., Tuazon J. et al.: Comparison of the flow properties of aqueous suspension corticosteroid nasal sprays under differing sampling conditions. Drug Dev. Ind. Pharm. 2003; 29: 1005-1012.
27. Salapatek A.M., Patel P., Gopalan G. et al.: Mometasone furoate nasal spray provides early, continuing relief of nasal congestion and improves nasal patency in allergic patients. Am. J. Rhinol. Allergy 2010; 24: 433-438.
28. Charakterystyka Produktu Leczniczego. Nasometin.
29. Charakterystyka Produktu Leczniczego. Pronasal.